REVIEW OF REIMBURSEMENT DECISION DRIVERS FOR RARE CANCER THERAPIES ACROSS EU5 MARKETS

被引：0
|
作者：
Gupta, J. [1 ]
Wahal, V. P. [2 ]
机构：
[1] DRG Abacus, Gurgaon, India
[2] DRG Market Access Insights, Gurgaon, India
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.965
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY138
引用
收藏
页码：A569 / A569
页数：1
相关论文
共 50 条
  • [31] MARKET ACCESS TRENDS ACROSS THE EU5: 2009 TO 2016-AN UPDATE
    Mycka, J.
    Dellamano, R.
    Lobb, W.
    Dalal, N.
    Dellamano, L.
    Pereira, M.
    Mora, M.
    VALUE IN HEALTH, 2017, 20 (09) : A677 - A677
  • [32] AN ANALYSIS OF PRICE AND ACCESS TIMELINE OF ONCOLOGY DRUGS ACROSS EU5 COUNTRIES
    Wang, X.
    VALUE IN HEALTH, 2018, 21 : S22 - S22
  • [33] UNDERSTANDING THE IMPACT OF REAL WORLD EVIDENCE ON REIMBURSEMENT DECISIONS ACROSS EU5 COUNTRIES USING A WEB-BASED PORTAL TO ENGAGE PAYERS
    Singh, Kumar K.
    Clapton, G. S.
    de Sousa, Rebelo C.
    Tripathi, S.
    VALUE IN HEALTH, 2018, 21 : S192 - S192
  • [34] COMPARISON OF PATIENT ACTIVATION LEVELS ACROSS VARIOUS CONDITIONS IN THE US AND EU5
    Annunziata, K.
    Sternbach, N.
    Carpinella, C. M.
    Chapnick, J.
    Patel, P.
    McDonald, M.
    McElwee, N.
    VALUE IN HEALTH, 2018, 21 : S140 - S140
  • [35] DO EU5 COUNTRIES WITH FAVOURABLE HEALTHCARE EXPENDITURE AND REIMBURSEMENT INDICATORS HAVE BETTER PATIENT-REPORTED ACCESS TO TREATMENTS FOR RARE DISEASES?
    Allen, G.
    Hall, A.
    Hanman, K.
    Le Fevre, R.
    Griffiths, A.
    VALUE IN HEALTH, 2017, 20 (09) : A409 - A410
  • [36] ACCEPTANCE OF PROGRESSION-FREE SURVIVAL 2 (PFS2) BY EU5 AND CANADIAN HEALTH AUTHORITIES FOR CANCER DRUG REIMBURSEMENT
    Rizzello, E.
    Leopaldi, C.
    Masso, B.
    Vidalis, A.
    Kachouh, P.
    Bechara, A.
    Milnes, J.
    VALUE IN HEALTH, 2022, 25 (01) : S184 - S184
  • [37] SINK OR SWIM: HOW CAN SLE BIOLOGICS SUCCESSFULLY ACHIEVE OPTIMAL REIMBURSEMENT AND UPTAKE IN THE EU5?
    Privolnev, Y.
    Albacker, C.
    Nasa, M.
    VALUE IN HEALTH, 2019, 22 : S51 - S52
  • [38] VARIATIONS IN STAKEHOLDER PREFERENCES BETWEEN INNOVATIVE PRICING AGREEMENT TYPES ACROSS THE EU5
    Edwards, G.
    Staufer, A.
    Dunlop, W.
    VALUE IN HEALTH, 2016, 19 (07) : A470 - A470
  • [39] INNOVATIVE REIMBURSEMENT AGREEMENTS ADDRESSING THE CHALLENGES OF ADVANCED THERAPY MEDICINAL PRODUCTS: SYSTEMATIC REVIEW FOR THE FIVE MAJOR EUROPEAN HEALTHCARE SYSTEMS (EU5)
    Spelsberg, R.
    Trappe, L.
    Govers, M.
    Evers, S.
    VALUE IN HEALTH, 2024, 27 (12) : S321 - S321
  • [40] EPIDEMIOLOGY OF MYASTHENIA GRAVIS IN US, EU5 AND JAPAN: A SYSTEMATIC LITERATURE REVIEW
    Kumar, S.
    Mishra, A.
    Dhami, Y.
    Sharma, S.
    Bergemann, R.
    VALUE IN HEALTH, 2020, 23 : S336 - S336
12345